The biosimilar testing services market is projected to grow from USD 4.4 billion in 2025 to USD 14.4 billion by 2035, at a CAGR of 12.5%. Pharmacokinetic Assay will dominate with a 38.2% market share, while elisa will lead the test type segment with a 44.7% share.